26.8 C
New York
Thursday, July 3, 2025

Tag: shareholders

CYMAT ANNOUNCES INVESTOR WEBINAR FOR MONDAY JULY 7 AT 11 AM

MISSISSAUGA, ON, July 3, 2025 /PRNewswire/ - Cymat Technologies Ltd. (TSXV: CYM) (OTCQB: CYMHF) (the "Company" or "Cymat") is pleased to announce that Michael...

Blüm Holdings Signs Agreement to Acquire Northern California Retail Dispensary

DOWNEY, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm,” “Blüm Holdings,” “we” or “us”), a California-based publicly traded holding company and cannabis operator, announced today that it has signed a binding agreement to acquire majority of the membership interests in another licensed adult-use and medical cannabis dispensary in Northern California.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Compass Diversified

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Compass To Contact Him Directly To Discuss Their Options If...

Middlefield Canadian Income PCC – Dividend Declaration

Middlefield Canadian Income PCC (the "Company")
Including Middlefield Canadian Income – GBP PC (the “Fund”), a cell of the Company
Registered No:  93546
Legal Entity Identifier: 2138007ENW3JEJXC8658

Transaction in Own Shares

LEI: 213800NNT42FFIZB1T09 
3 July 2025

Transaction in Own Shares

Transaction in Own Shares

Karolinska Development receives update from Organon concerning OG-6219

STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate.

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that it has entered into a binding arrangement agreement with CB Biotechnology, LLC (the “Purchaser”), an affiliate of Future Pak, LLC (“Future Pak”), a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products, whereby the Purchaser will acquire all the issued and outstanding common shares of the Company for US$3.01 per share in cash plus one contingent value right (“CVR”) per share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones as described below are achieved (the “Transaction”). The total Transaction consideration, assuming full payment of the CVRs, is US$254 million.

Strathcona Resources Ltd. Confirms Closing of Sale of Montney Business and Provides Update on MEG Strategic Alternatives Process

CALGARY, AB, July 2, 2025 /CNW/ - Strathcona Resources Ltd. ("Strathcona" or the "Company") (TSX: SCR) is pleased to confirm the closing of its...

Stellus Private Credit BDC Announces $0.38 Third Quarter 2025 Regular Dividend, Payable Monthly in Increments of $0.1266 in July, August, and September 2025

HOUSTON, July 2, 2025 /PRNewswire/ -- Stellus Private Credit BDC ("the Company") announced that its Board of Trustees has declared a monthly dividend of...

Hims & Hers Health, Inc. (HIMS) Faces Securities Class Actions After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy– Hagens Berman

HIMS Investors with Losses Encouraged to Contact Hagens Berman
HIMS Investors with Losses Encouraged to Contact Hagens Berman

NuVista Energy Ltd. Announces Updated Annual Production Guidance Due to Third Party Midstream Delays

CALGARY, Alberta, July 02, 2025 (GLOBE NEWSWIRE) -- NuVista Energy Ltd. (TSX:NVA, "NVA" or "NuVista") is providing revised guidance to our annual production volumes and reiterating our commitment to our shareholder return strategy. Due to continued delays in commissioning the Pipestone Gas Plant (“Pipestone Plant”) and additional required work discovered during a gas plant turnaround in the greater Wapiti area (“Wapiti Turnaround”), we now anticipate annual volumes to average approximately 83,000 Boe/d(1). The impact of the delays due to the Pipestone Plant and Wapiti Turnaround on annual production volumes is approximately 3,500 Boe/d and 6,000 Boe/d, respectively. Both third-party facilities are expected to be fully operational prior to September.

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Launch One Acquisition Corp. (NASDAQ: LPAA)

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Launch One Acquisition Corp. (NASDAQ: LPAA) related to its merger with Minovia Therapeutics Ltd., in which Launch One shareholders will be eligible for a one-to-one exchange of shares in the new company, Mito US One Ltd. Is it a fair deal?

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsShareholders